Thomas L Andersen1,2, Christina Baun1, Birgitte B Olsen1,2, Johan H Dam1,2, Helge Thisgaard3,2. 1. PET Unit, Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark; and. 2. Department of Clinical Research, University of Southern Denmark, Odense, Denmark. 3. PET Unit, Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark; and helge.thisgaard@rsyd.dk.
Abstract
PET imaging at late time points after injection may allow tracer clearance from normal tissue and hence improve image contrast and detectability. 55Co is a promising isotope with high positron yield and a long half-life suitable for imaging at delayed time points. Here, we compared the 3 radioconjugates [68Ga]Ga-DOTATATE, [64Cu]Cu-DOTATATE, and [55Co]Co-DOTATATE by PET/CT imaging in NOD-SCID mice bearing subcutaneous somatostatin receptor-expressing AR42J tumors. Methods: 55Co and 64Cu were produced by the 54Fe(d,n)55Co and 64Ni(p,n)64Cu nuclear reactions, whereas 68Ga was obtained from a 68Ge/68Ga generator. 55Co and 64Cu were labeled with DOTATATE by heating in a sodium acetate buffer and 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid buffer, respectively. AR42J tumor-bearing mice were dynamically scanned 0-1 h after injection. For 64Cu and 55Co, additional imaging was also performed at late time points after 4 and 24 h. Dose calculations were based on a known biodistribution. The cumulated disintegrations in each organ were calculated by integration of a fitted exponential function to the biodistribution of each respective organ. Equivalent doses were calculated by OLINDA/EXM using the MIRD formalism. Results: Tumor uptake was rapid from 0 to 1 h after injection for all 3 radioconjugates. Normal-tissue ratios as represented by tumor-to-liver, tumor-to-kidney, and tumor-to-muscle ratios increased significantly over time, with [55Co]Co-DOTATATE reaching the highest ratio of all radioconjugates. For [55Co]Co-DOTATATE, the tumor-to-liver ratio increased to 65 ± 16 at 4 h and 50 ± 6 at 24 h, which were 15 (P < 0.001) and 30 (P < 0.001) times higher, respectively, than the corresponding ratios for [64Cu]Cu-DOTATATE and 5 (P < 0.001) times higher than that of [68Ga]Ga-DOTATATE at 1 h. Correspondingly, tumor-to-kidney and tumor-to-muscle ratios for [55Co]Co-DOTATATE were 4 (P < 0.001) and 11 (P < 0.001) times higher than that of [64Cu]Cu-DOTATATE at 24 h. An equivalent dose was calculated as 9.6E-02 mSv/MBq for [55Co]Co-DOTATATE. Conclusion: [55Co]Co-DOTATATE demonstrated superior image contrast compared with [64Cu]Cu-DOTATATE and [68Ga]Ga-DOTATATE for PET imaging of somatostatin receptor-expressing tumors, warranting translation into clinical trials. Dosimetry calculations found that effective doses for [55Co]Co-DOTATATE were comparable to those for both [64Cu]Cu-DOTATATE and [68Ga]Ga-DOTATATE.
PET imaging at late time points after injection may allow tracer clearance from normal tissue and hence improve image contrast and detectability. 55Co is a promising isotope with high positron yield and a long half-life suitable for imaging at delayed time points. Here, we compared the 3 radioconjugates [68Ga]Ga-DOTATATE, [64Cu]Cu-DOTATATE, and [55Co]Co-DOTATATE by PET/CT imaging in NOD-SCID mice bearing subcutaneous somatostatin receptor-expressing AR42J tumors. Methods: 55Co and 64Cu were produced by the 54Fe(d,n)55Co and 64Ni(p,n)64Cu nuclear reactions, whereas 68Ga was obtained from a 68Ge/68Ga generator. 55Co and 64Cu were labeled with DOTATATE by heating in a sodium acetate buffer and 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid buffer, respectively. AR42J tumor-bearing mice were dynamically scanned 0-1 h after injection. For 64Cu and 55Co, additional imaging was also performed at late time points after 4 and 24 h. Dose calculations were based on a known biodistribution. The cumulated disintegrations in each organ were calculated by integration of a fitted exponential function to the biodistribution of each respective organ. Equivalent doses were calculated by OLINDA/EXM using the MIRD formalism. Results: Tumor uptake was rapid from 0 to 1 h after injection for all 3 radioconjugates. Normal-tissue ratios as represented by tumor-to-liver, tumor-to-kidney, and tumor-to-muscle ratios increased significantly over time, with [55Co]Co-DOTATATE reaching the highest ratio of all radioconjugates. For [55Co]Co-DOTATATE, the tumor-to-liver ratio increased to 65 ± 16 at 4 h and 50 ± 6 at 24 h, which were 15 (P < 0.001) and 30 (P < 0.001) times higher, respectively, than the corresponding ratios for [64Cu]Cu-DOTATATE and 5 (P < 0.001) times higher than that of [68Ga]Ga-DOTATATE at 1 h. Correspondingly, tumor-to-kidney and tumor-to-muscle ratios for [55Co]Co-DOTATATE were 4 (P < 0.001) and 11 (P < 0.001) times higher than that of [64Cu]Cu-DOTATATE at 24 h. An equivalent dose was calculated as 9.6E-02 mSv/MBq for [55Co]Co-DOTATATE. Conclusion: [55Co]Co-DOTATATE demonstrated superior image contrast compared with [64Cu]Cu-DOTATATE and [68Ga]Ga-DOTATATE for PET imaging of somatostatin receptor-expressing tumors, warranting translation into clinical trials. Dosimetry calculations found that effective doses for [55Co]Co-DOTATATE were comparable to those for both [64Cu]Cu-DOTATATE and [68Ga]Ga-DOTATATE.
Authors: J A Siegel; S R Thomas; J B Stubbs; M G Stabin; M T Hays; K F Koral; J S Robertson; R W Howell; B W Wessels; D R Fisher; D A Weber; A B Brill Journal: J Nucl Med Date: 1999-02 Impact factor: 10.057
Authors: Michael Gabriel; Clemens Decristoforo; Eveline Donnemiller; Hanno Ulmer; Christine Watfah Rychlinski; Stephen J Mather; Roy Moncayo Journal: J Nucl Med Date: 2003-05 Impact factor: 10.057
Authors: E P Krenning; D J Kwekkeboom; W H Bakker; W A Breeman; P P Kooij; H Y Oei; M van Hagen; P T Postema; M de Jong; J C Reubi Journal: Eur J Nucl Med Date: 1993-08
Authors: Sophie Waldvogel-Abramowski; Gérard Waeber; Christoph Gassner; Andreas Buser; Beat M Frey; Bernard Favrat; Jean-Daniel Tissot Journal: Transfus Med Hemother Date: 2014-05-12 Impact factor: 3.747
Authors: Axel Heppeler; João P André; Ingeborg Buschmann; Xuejuan Wang; Jean-Claude Reubi; Michael Hennig; Thomas A Kaden; Helmut R Maecke Journal: Chemistry Date: 2008 Impact factor: 5.236
Authors: Andrey G Kazakov; Julia S Babenya; Taisya Y Ekatova; Sergey S Belyshev; Vadim V Khankin; Alexander A Kuznetsov; Sergey E Vinokurov; Boris F Myasoedov Journal: Molecules Date: 2022-02-24 Impact factor: 4.411
Authors: Yohana C Toner; Adam A Ghotbi; Sonum Naidu; Ken Sakurai; Mandy M T van Leent; Stefan Jordan; Farideh Ordikhani; Letizia Amadori; Alexandros Marios Sofias; Elizabeth L Fisher; Alexander Maier; Nathaniel Sullivan; Jazz Munitz; Max L Senders; Christian Mason; Thomas Reiner; Georgios Soultanidis; Jason M Tarkin; James H F Rudd; Chiara Giannarelli; Jordi Ochando; Carlos Pérez-Medina; Andreas Kjaer; Willem J M Mulder; Zahi A Fayad; Claudia Calcagno Journal: Sci Rep Date: 2022-04-13 Impact factor: 4.379
Authors: Sara S Rinne; Charles Dahlsson Leitao; Zahra Saleh-Nihad; Bogdan Mitran; Vladimir Tolmachev; Stefan Ståhl; John Löfblom; Anna Orlova Journal: Int J Mol Sci Date: 2020-03-13 Impact factor: 5.923